Endoxan Baxter 1 g Polvere per soluzione iniettabile

DRUG2 trials

Sponsors

Cabaletta Bio Inc., Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS

Conditions

Active Idiopathic Inflammatory Myopathy including dermatomyositisanti-synthetase syndromebreast cancerimmune-mediated necrotizing myopathy or Juvenile Idiopathic Inflammatory Myopathy

Phase 1

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy

Not yet recruitingCTIS2025-521145-24-01

Cabaletta Bio Inc.Active Idiopathic Inflammatory Myopathy including dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy or Juvenile Idiopathic Inflammatory Myopathy

Target: 13Updated: 2026-04-30

Phase 2

Optimization of De-EscalatiON strategies in early breast cancer

Not yet recruitingCTIS2026-527524-27-00

Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCSbreast cancer

Target: 1Updated: 2026-09-14